SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Cohen who wrote (1312)10/12/1997 1:44:00 PM
From: Pseudo Biologist   of 1762
 
Richard, Eric Hecht, biotech analyst at Merryl Lynch, recently put out a report estimating a $400 million market for IDEC's anti-CD20 program (C2B8 with or without CHOP, Y2B8) by the year 2001. Based on his projections, which he thinks will lead to a EPS of $1.50 by 1999, he has a 12-month target price of $53 for the stock. The report, dated October 2 increased previous estimates after Hecht surveyed a number of oncologists in the US.

This projections do not include significant contributions from the current pipeline. This includes the anti-CD4 program, which at the moment I see as a 50/50 gamble, the topoisomerase inhbitor for cancer, a nice but perhaps not a blockbuster product, a very interesting anti-gp39 program about to enter phase I clinical (thus still too early to tell, but a potential blockbuster IMO), plus a number of other things I have not thought much about recently.

Hope this helps some,

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News